Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Primary Plasma Cell Leukemia Phase II Study With Daratumumab Plus Chemotherapy and Stem Cell Transplantation
2019-004170-26Phase 2Active
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Feb 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of daratumumab in plasma cell leukaemia (PCL), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Best overall response rate (VGPR or better) at completion of induction. Started Feb 2021; status: active.
02
Drugs
daratumumab
03
Conditions
plasma cell leukaemia (PCL)
Beyond the preview
Go deeper on 2019-004170-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004170-26.